Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Leases (Tables)

Leases (Tables)

3 Months Ended

Feb. 28, 2022

The following table presents the right-of-use asset and short-term and long-term lease liabilities amounts recorded on the consolidated balance sheets as of February 28, 2022 and November 30, 2021:


	February 28, 2022		November 30, 2021
Assets
Operating lease right-of-use asset	$	839,889	$	916,493
Liabilities
Current portion of operating lease liabilities	$	315,860	$	312,067
Operating lease long-term liabilities		530,941		610,989
Total lease liability	$	846,801	$	923,056

Summary of Maturity of the Company's Lease Liabilities

The maturity of the Company’s lease liabilities at February 28, 2022 were as follows:


	Future Operating
Fiscal Year Ending November 30,	Lease Payments
2022 (remaining 9 months)	$	255,137
2023		313,996
2024		295,086
2025		24,591
Less: Imputed interest		(42,009	)
Present value of lease liabilities	$	846,801

Summary of Remaining Lease Term and Discount Rates

The remaining lease term and discount rates are as follows:


	February 28, 2022	November 30, 2021
Lease Term and Discount Rate
Remaining lease term (years)
Operating lease	2.83		3.08
Discount rate (percentage)
Operating lease	3.5%		3.5	%

Summary of Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases is as follows:


	Three months ended
	February 28, 2022		February 28, 2021
Operating cash outflows from operating leases	$	85,964	$	71,566